Back to News

ETAR Blockade’s Role in Current and Emerging Therapies for IgAN- Explore the Visual Abstract

Click on the image to expand

This visual abstract was supported by an unrestricted educational grant from Chinook Therapeutics, a Novartis company.

Help us advance kidney health worldwide
Join the ISN Subscribe to ISN Newsletter
Back to News